These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

685 related items for PubMed ID: 18379296

  • 1. Update of prostate magnetic resonance imaging at 3 T.
    Kim CK, Park BK.
    J Comput Assist Tomogr; 2008; 32(2):163-72. PubMed ID: 18379296
    [Abstract] [Full Text] [Related]

  • 2. Prostate cancer detection: comparison of T2-weighted imaging, diffusion-weighted imaging, proton magnetic resonance spectroscopic imaging, and the three techniques combined.
    Chen M, Dang HD, Wang JY, Zhou C, Li SY, Wang WC, Zhao WF, Yang ZH, Zhong CY, Li GZ.
    Acta Radiol; 2008 Jun; 49(5):602-10. PubMed ID: 18568549
    [Abstract] [Full Text] [Related]

  • 3. Usefulness of diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging in the diagnosis of prostate transition-zone cancer.
    Yoshizako T, Wada A, Hayashi T, Uchida K, Sumura M, Uchida N, Kitagaki H, Igawa M.
    Acta Radiol; 2008 Dec; 49(10):1207-13. PubMed ID: 19031184
    [Abstract] [Full Text] [Related]

  • 4. Thirty-two-channel coil 3T magnetic resonance-guided biopsies of prostate tumor suspicious regions identified on multimodality 3T magnetic resonance imaging: technique and feasibility.
    Hambrock T, Fütterer JJ, Huisman HJ, Hulsbergen-vandeKaa C, van Basten JP, van Oort I, Witjes JA, Barentsz JO.
    Invest Radiol; 2008 Oct; 43(10):686-94. PubMed ID: 18791410
    [Abstract] [Full Text] [Related]

  • 5. Comparison of phased-array 3.0-T and endorectal 1.5-T magnetic resonance imaging in the evaluation of local staging accuracy for prostate cancer.
    Park BK, Kim B, Kim CK, Lee HM, Kwon GY.
    J Comput Assist Tomogr; 2007 Oct; 31(4):534-8. PubMed ID: 17882027
    [Abstract] [Full Text] [Related]

  • 6. Inter-reader agreement of multi-parametric MR imaging for the detection of prostate cancer: evaluation of a scoring system.
    Quentin M, Arsov C, Röhlen S, Klasen J, Antoch G, Albers P, Blondin D.
    Rofo; 2012 Oct; 184(10):925-9. PubMed ID: 22744328
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. MR imaging and MR spectroscopy in prostate cancer management.
    Katz S, Rosen M.
    Radiol Clin North Am; 2006 Sep; 44(5):723-34, viii. PubMed ID: 17030223
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Functional magnetic resonance imaging in prostate cancer.
    Seitz M, Shukla-Dave A, Bjartell A, Touijer K, Sciarra A, Bastian PJ, Stief C, Hricak H, Graser A.
    Eur Urol; 2009 Apr; 55(4):801-14. PubMed ID: 19185981
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Prostate cancer screening: the clinical value of diffusion-weighted imaging and dynamic MR imaging in combination with T2-weighted imaging.
    Tanimoto A, Nakashima J, Kohno H, Shinmoto H, Kuribayashi S.
    J Magn Reson Imaging; 2007 Jan; 25(1):146-52. PubMed ID: 17139633
    [Abstract] [Full Text] [Related]

  • 20. Analysis of prostate DCE-MRI: comparison of fast exchange limit and fast exchange regimen pharmacokinetic models in the discrimination of malignant from normal tissue.
    Lowry M, Zelhof B, Liney GP, Gibbs P, Pickles MD, Turnbull LW.
    Invest Radiol; 2009 Sep; 44(9):577-84. PubMed ID: 19668002
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.